VLX 600
Alternative Names: VLX600Latest Information Update: 28 Jun 2021
Price :
$50 *
At a glance
- Originator Karolinska Institute; Vivolux
- Developer Vivolux
- Class Cytostatics; Indoles; Methylhydrazines; Pyridines; Small molecules
- Mechanism of Action Iron chelating agents; Mitochondrial oxidative phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours(Refractory metastatic disease) in USA (IV, Infusion)
- 24 Aug 2018 Phase I development is ongoing in USA (Vivolux pipeline, August 2018)
- 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Refractory metastatic disease) in USA (IV, Infusion)